< GPCR News < GPCRs in Oncology and Immunology CB2 stimulation of adipose resident ILC2s orchestrates Here, we demonstrate that CB2, a G-protein-coupled receptor (GPCR) and member of the endocannabinoid combination of ex vivo and in vivo approaches to explore the functional and therapeutic impacts of CB2 Our results show that CB2 stimulation of ILC2s protects against insulin-resistance onset, ameliorates Our mechanistic studies reveal that the therapeutic effects of CB2 are mediated through activation of

GPR35, muscarinic acetylcholine receptor M3, alpha-1A adrenergic receptor α1A and cannabinoid receptor CB2

2010 after studying the orphan atypical cannabinoid receptor, GPR55 and its crosstalk with CB1R and CB2R